IgGenix is a Biotech company based in South San Francisco, CA. It has raised $65M in total funding. Latest round: Series B.
IgGenix funding overview
IgGenix is a Biotech company based in South San Francisco, CA. IgGenix has raised $65M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in February 2023. The round record for IgGenix runs through 2023; nothing later has been disclosed. Investors on record include Alexandria Venture Investments, Eli Lilly and Company, Khosla Ventures, Sean Parker, AllerFund. 5 distinct backers are named across the disclosed rounds.
IgGenix at a glance
Total raised
$65M
Latest round
Series B
Latest round date
February 2023
Industry
Biotech
Headquarters
South San Francisco, CA
Notable investors
Alexandria Venture Investments, Eli Lilly and Company, Khosla Ventures, Sean Parker, AllerFund
Frequently asked about IgGenix funding
How much has IgGenix raised?
IgGenix has raised $65M in total disclosed funding across the rounds on record.
Who has invested in IgGenix?
Alexandria Venture Investments, Eli Lilly and Company, Khosla Ventures, Sean Parker, AllerFund are named among the investors backing IgGenix.
What was the latest IgGenix funding round?
The most recent disclosed round is a Series B, announced in February 2023.
Where is IgGenix based?
IgGenix is based in South San Francisco, CA.
What sector does IgGenix operate in?
IgGenix is tracked under Biotech from South San Francisco, CA, with $65M in disclosed funding.
When did IgGenix last raise?
The last disclosed IgGenix round closed in February 2023 at Series B.
Round data for IgGenix is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the Biotech companies in South San Francisco and backer lists below.
